Rani Therapeutics gets FDA Emerging Technology Program acceptance, updates RT-114 enrollment
Rani reported third-quarter 2026 results, citing the FDA program acceptance and continued RT-114 expansion enrollment alongside a cash runway statement through at least the end of 2027.
SEC filing